Article

Study Identifies Potential Target to Reduce Liver Damage, Prevent Cancer

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer, according to a new study published in the Journal of Clinical Investigation.

A triggering receptor expressed on myeloid cells-1, also known as TREM-1, activates inflammation short-term following an insult, such as a laceration, or in response to external invaders, such as bacteria. However, for the first time, researchers have found that, when activated by chronic offending agents such as hepatitis and obesity, TREM-1 can contribute to a destructive level of inflammation that results in liver damage and possibly cancer.

According to the researchers, this transformation can occur in 5 to 50 years, and could be reversible up to the point of cirrhosis if the offending agent is stopped. The findings suggest that potentially targeting this receptor on Kupffer cells, the liver’s resident macrophages, could return TREM-1 activation to normal levels to reduce damage.

“Right now we have a treatment for hepatitis C, for example, which is very efficient, if we treat it before too much damage is done,” study author Anatolij Horuzsko, PhD, reproductive immunologist in the Georgia Cancer Center and Department of Medicine at the Medical College of Georgia at Augusta University, said in a prepared statement. “But we don’t have treatment for alcohol- or obesity-related damage.”

Read the full article at SpecialtyPharmacyTimes.com.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com